We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · May 24, 2022

Efficacy of Once-Weekly Semaglutide vs Thrice-Daily Insulin Aspart as Add-On to Metformin and Insulin Glargine in Type 2 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial
Diabetes Obes Metab 2022 May 11;[EPub Ahead of Print], M Kellerer, MS Kaltoft, J Lawson, LL Nielsen, K Strojek, Ö Tabak, S Jacob

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading